Hemorrhage
Bleeding or escape of blood from a vessel.
Subtype terms (21)
More specific conditions that are subtypes of Hemorrhage in the MeSH hierarchy.
- Blood Loss, Surgical
67 drugs (48 approved, 19 experimental)
- Ecchymosis
11 drugs (9 approved, 2 experimental)
- Epistaxis
26 drugs (18 approved, 8 experimental)
- Exsanguination
- Eye Hemorrhage
- Gastrointestinal Hemorrhage
28 drugs (24 approved, 4 experimental)
- Hemarthrosis
2 drugs (1 approved, 1 experimental)
- Hematocele
3 drugs approved
- Hematoma
18 drugs (13 approved, 5 experimental)
- Hematuria
14 drugs approved
- Hemobilia
- Hemoperitoneum
- Hemoptysis
8 drugs (7 approved, 1 experimental)
- Hemothorax
1 drug approved
- Intracranial Hemorrhages
52 drugs (44 approved, 8 experimental)
- Oral Hemorrhage
4 drugs approved
- Postoperative Hemorrhage
28 drugs (23 approved, 5 experimental)
- Purpura
60 drugs (38 approved, 22 experimental)
- Retrobulbar Hemorrhage
- Shock, Hemorrhagic
19 drugs (13 approved, 6 experimental)
- Uterine Hemorrhage
23 drugs (18 approved, 5 experimental)
Drugs by status
Approved for this indication (52)
- diclofenac
- ringer's lactate
- norgestrel
- desmopressin
- oxytocin
- andexanet alfa
- aprotinin
- human fibrin
- autologous blood
- autologous plasma
- dextran
- emicizumab
- ferric sulfate
- carboprost tromethamine
- idarucizumab
- somatostatin
- metaraminol
- serum
- prasugrel
- red blood cells
- celecoxib
- gelofusin
- whole blood
- yunnan baiyao
- aminocaproic acid
- sodium acetate
- danshen
- zinc dichloride
- napthoquine
- eclipta prostrata
- +22 more
Phase 4 trials (66)
- edoxaban
- nitroglycerin
- heparin
- avatrombopag
- argatroban
- procaine benzylpenicillin
- dabigatran
- umirolimus
- carbetocin
- medicinal charcoal
- ketamine
- clavulanate
- doxycycline
- betamethasone
- valproic acid
- ecabet
- amlodipine
- famotidine
- albumin (Human)
- fibrinogen (human)
- insulin human
- warfarin
- hydrocortisone
- indapamide
- desogestrel
- metoclopramide
- nicardipine
- human factor ix complex (prothrombin complex concentrate)
- atorvastatin
- ticagrelor
- +36 more
Phase 3 trials (42)
- simvastatin
- ilaprazole
- sintrom
- vitamin e
- clevidipine
- cyanoacrylate
- diltiazem
- nifedipine
- ergonovine
- Diatrizoate
- iodine
- nimodipine
- vitamin c
- phenindione
- sodium picosulfate
- honey
- prucalopride succinate
- epinephrine
- coagulation factor viia (recombinant)
- platelets
- hyaluronic acid
- estradiol
- resveratrol
- aflibercept
- bivalirudin
- midazolam
- sodium phosphate
- anti-inhibitor coagulant complex (activated prothrombin complex concentrate)
- sodium tetradecyl sulfate
- dobesilic acid
- +12 more
Phase 2 trials (29)
- propofol
- vitamin d3
- mirabegron
- betrixaban
- epoetin
- dantrolene
- dapivirine
- eltrombopag
- sevoflurane
- tacrolimus
- ginger
- icosapent ethyl
- mdco-2010
- meloxicam
- peprostat
- bevacizumab
- phenprocoumon
- umbilical cord mesenchymal stem cells
- decidual stromal cells
- glucagon-like peptide-1
- siponimod
- tamoxifen
- anakinra
- levonorgestrel
- ferrous sulfate
- sodium copper chlorophyllin
- COVID-19 convalescent plasma
- bge-117
- bxp154
Phase 1 trials (14)
Other trials (24)
Organizations
Organization Involved with Phase 4 Indications (274)
- Chinese University of Hong Kong
- Far Eastern Memorial Hospital
- Leiden University
- University of Paris
- The Medicines Company
- Rocky Vista University
- University of Oslo
- Taichung Veterans General Hospital
- Eastern Maine Medical Center
- Chang Gung University
- Mayo Clinic
- University of New South Wales
- Thomas Jefferson University
- University of Texas at Houston
- Methodist Healthcare
- University of Iowa
- Women's Health Care Clinic, Torrance, California
- Kowng Wah Hospital
- Hédi Chaker Hospital
- Pennsylvania State University
- AMAG Pharmaceuticals, Inc.
- University of Saskatchewan
- Government of France
- Guangdong Second Provincial Traditional Chinese Medicine Hospital
- Johannes Kepler University
- University of The West Indies
- Maastricht University
- Northwestern University
- Tianjin Second People's Hospital
- University of California, Los Angeles
- +244 more
Organization Involved with Phase 3 Indications (222)
- University of Manchester
- Singapore General Hospital
- British Heart Foundation
- Institut National de la Santé Et de la Recherche Médicale, France
- Pharmacosmos
- University of Rennes
- Elisabeth-TweeSteden Ziekenhuis
- Reinier de Graaf Groep
- The University of Hong Kong
- The Foundation of 17.12.1981
- Sinai Health System
- Total Definer Research Group
- Case Western Reserve University
- National Institute of Neurological Disorders and Stroke (NINDS)
- University of Waterloo
- Omrix Biopharmaceuticals, Inc.
- Bausch & Lomb
- Action Research Group
- Free University of Amsterdam
- University of the West of England
- Actelion
- Allergan
- Idorsia Pharmaceuticals Ltd.
- National University of Ireland
- Kaiser Foundation
- University of New Mexico
- German Heart Institute
- Fresenius
- Medical University of Vienna
- Daiichi Sankyo
- +192 more
Organization Involved with Phase 2 Indications (97)
- Hoosier Cancer Research Network
- Osaka University
- Sangart
- Prolong Pharmaceuticals
- ZonMw: The Netherlands Organisation for Health Research and Development
- BIT Pharma GmbH
- Laboratorio Elea S.A.C.I.F. y A.
- Federal University of Rio Grande do Sul
- Food and Drug Administration
- BTG
- University of Pavia
- Evgen Pharma
- Alex Ekwueme Federal University Teaching Hospital
- University of Southern California
- Swiss Neonatal Network
- National Neuroscience Institute
- Data Magik Ltd
- Hope Pharmaceuticals
- University of Padua
- GlaxoSmithKline
- Hopital de l'Enfant-Jesus
- Melbourne Health
- Orion Corporation
- City University of Hong Kong
- Chulalongkorn University
- Population Council
- State University of New York, Buffalo
- Duramed Research
- NoNO Inc.
- Government of China
- +67 more
Organization Involved with Phase 1 Indications (32)
- RTI International
- Sheila B. Terry Memorial Research Fund
- Department of Health and Human Services
- Wake Forest University
- Hormozgan University of Medical Sciences
- Cellphire, Inc.
- Baylor University
- Pharmaxi LLC
- Minia University
- Lagos State University
- University of Adelaide
- Johnson and Johnson
- Children's National Medical Center
- Yantai YenePharma Co., Ltd.
- Guangzhou Medical University
- University of California, Irvine
- University of California, Riverside
- University of Manitoba
- Shenzhen Hornetcorn Bio-technology Company, LTD
- Dr. Jeffrey Thomas Stroke Shield Foundation
- Oxytone Bioscience BV
- Medical College of Wisconsin
- Bangladesh Medical University
- Pharmaron
- University of Missouri
- Neurop Inc.
- University of Mississippi
- Thoratec
- LFB Biotechnologies, SAS
- inVentiv
- +2 more
Organization Involved with Other Experimental Indications (114)
- Shenzhen University
- Malmö University
- Nanhai Maternity & Child Healthcare Hospital
- Dr. Sami Ulus Children's Hospital
- Jiangsu Chia-tai Tianqing Pharmaceutical Co.,Ltd
- King Abdul-Aziz University
- Sisters of Mercy University Hospital
- Guangxi Medical University
- Kurdistan Board for Medical Speciality
- National Center for Complementary and Integrative Health (NCCIH)
- Secretariat of His Highness the Aga Khan, Aiglemont
- Medical Centre of Postgraduate Education, Poland
- Jhpiego
- Hospital Gineco Obstetrico Isidro Ayora
- Cardialysis BV
- National University of Malaysia
- One Heart Project
- University of South Carolina
- MOH Etlik Zubeyde Hanim Women's Health Training and Research Hospital
- University of Pretoria
- Terumo Corporation
- Shandong Provincial Hospital
- University of Ljubljana
- University of Cape Town
- Anhui College of Traditional Chinese Medicine
- Norton Healthcare
- University of Picardie Jules Verne
- Zekai Tahir Burak Hospital
- Gilead Sciences
- Second People's Hospital of Lanzhou
- +84 more